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Abstract
Background: Achieving durable local control while limiting normal tissue toxicity with definitive radiation therapy
in the management of high-risk brain metastases remains a radiobiological challenge. The objective of this study
was to examine the local control and toxicity of a 5-fraction stereotactic radiosurgical approach for treatment of
patients with inoperable single high-risk NSCLC brain metastases.
Methods: This retrospective analysis examines 20 patients who were deemed to have “high-risk” brain metastases.
High-risk tumors were defined as those with a maximum diameter greater than 2 cm and/or those located within an
eloquent cortex. Patients were evaluated by a neurosurgeon prior to treatment and determined to be inoperable due
to tumor or patient characteristics. Patients were treated using the CyberKnife® SRS system in 5 fractions to a total dose
of 30 Gy, 35 Gy, or 40 Gy.
Results: Twenty patients with a median age of 65.5 years were treated from April 2010 to August 2014 in 5
fractions to a median total dose of 35 Gy. At a median follow up of 11.3 months local tumor control was
observed in 18 of 20 metastases (90 %). Both local failures were observed in patients receiving a lower dose
of 30 Gy. Median pre-treatment dexamethasone dose was 10 mg/day and median post-treatment nadir dose
was 0 mg/day. Salvage intracranial therapy was required in 45 % of patients. Symptomatic radionecrosis was observed
in 4 of 20 patients (20 %), two of which were treated to 40 Gy and the remainder to 35 Gy. Kaplan-Meier 1-year, 2-year,
and median survival were calculated to be 45 %, 20 %, and 13.2 months, respectively.
Conclusions: Five-fraction SRS to a total dose of 35 Gy appears to be a safe and effective management strategy for
single high-risk NSCLC brain metastases, while a total dose of 40 Gy leads to an excess risk of neurotoxicity.
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Background
The incidence of brain metastases in the U.S. is estimated
to be as high as 170,000 cases per year [1]. Due to the
wider utilization of MRI and more effective systemic ther-
apy the incidence of brain metastases has risen over the
past 20 years [1]. Lung cancer accounts for the majority
(40 % to 50 %) of these brain metastases with 43 % of
patients with NSCLC developing brain metastases alone
with no other evidence of extracranial metastatic disease
[2, 3]. The management of brain metastases varies based
on an individual’s prognosis, lesion location, number of
lesions, and size of said lesions. Although initial surgical
resection remains the standard of care for solitary and sin-
gle brain metastases in good performance status patients
with controlled primary tumors, oftentimes lesions are
deemed too high risk for surgery either due to patient or
tumor characteristics. In these non-surgical candidates
definitive conventional radiation had been historically
employed. However, despite providing early palliation of
symptoms, whole-brain radiotherapy (WBRT) has been
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associated with increased late neurotoxicity and a
decreased quality of life [4].
In an effort to enhance local tumor control and
minimize radiation toxicity there has been a modern
movement to employ definitive SRS in the treatment of
a finite number of brain lesions. However, much of this
prospective research has revolved around single-fraction
SRS treatments. Results of RTOG 90–05 developed
maximum tolerated single-fraction doses of 24 Gy,
18 Gy, and 15 Gy based on tumor sizes of ≤ 2.0, 2.1-3.0,
and 3.1-4.0 cm, respectively [5]. Importantly, on multi-
variate analysis maximum tumor diameter was signifi-
cantly associated with an elevated risk of neurotoxicity
with tumors 2.1-4.0 cm having a 7.3 to 16 times higher
risk of developing grade 3–5 neurotoxicity compared to
tumors < 2.0 cm. The relationship between large tumor
size and/or eloquence of tumor location has been estab-
lished in the literature [5–7]. As a result, new investiga-
tions into the utility of hypofractionated treatment
regimens have sought to exploit the radiobiological prop-
erties of normal surrounding tissue [8, 9].
The accuracy and flexibility of the CyberKnife halo-free
system prompted our institution in early 2010 to evaluate
a 5-fraction SRS treatment approach for single NSCLC
brain metastases [10]. The system’s unique configuration
facilitates the accurate delivery of fractionated high dose
radiation, despite the close proximity of such tumors to
radiation sensitive brain tissue. In the present study we
report outcomes for 20 consecutively treated, eligible
patients with newly diagnosed single high-risk NSCLC
brain metastases treated using this novel approach.
Methods
Eligibility
The MedStar Health Research Institute - Georgetown
University Oncology Institutional Review Board, ap-
proved this retrospective analysis of an established
departmental treatment approach. Twenty consecutive
patients with single high-risk NSCLC brain metastases
were treated in 5 fractions with the SRS frame-free
CyberKnife system between April 2010 and August 2014
and were available for our analysis. Patients were
deemed to have high-risk lesions if the maximum diam-
eter was greater than 2 cm and/or was located within an
eloquent cortex. Eloquent cortex was determined in con-
cert with the attending neurosurgeon and was defined as
a lesion localized to cortex responsible for language, vi-
sion, sensation, and/or motor function. Patients were
evaluated by a neurosurgeon prior to treatment and
determined not to be operable candidates due to tumor
or patient characteristics. Prohibitive patient characteris-
tics included life expectancies under 3 months and sig-
nificant medical co-morbidities. Life expectancy was
typically evaluated by both neurosurgery and radiation
oncology physicians prior to treatment. Life expectancy
was determined by using a combination of ECOG per-
formance status and the RPA prognostic classification.
Patients with previously irradiated brain tumors or
multiple brain tumors at presentation were excluded.
Treatment planning and delivery
A fine-cut (1.25 mm) contrast enhanced treatment plan-
ning CT scan was obtained in the supine treatment pos-
ition for each patient using a GE LightSpeed RT16. MRI
of the brain was obtained in all 20 patients prior to
radiotherapy for diagnosis and evaluation. Additional
MRI imaging for treatment planning was completed
when deemed necessary by the attending physician. Pre-
treatment MRIs were fused with the planning CT scans
and in the majority of cases were used for target volume
delineation. Brain metastases were contoured without
expansion on all visualized axial image slices of the plan-
ning CT scan and/or fused MRI. In cases where the
lesion was clearly visible on the planning CT, target vol-
ume delineation was performed on the simulation CT
scan with MRI volume verification. A treatment plan
was generated using the MultiPlan 5.2.1 non-isocentric
inverse-planning algorithm. Radiation was delivered in 5
equal fractions of 6 to 8 Gy prescribed to an isodose line
that covered at least 95 % of the GTV. Patients were
treated in the supine position with a custom aquaplast
mask for immobilization and reproducible patient set-
up. The standard SRS treatment schedule was to deliver
5 fractions over 5 consecutive days. Treatment length
was calculated based on the total number of elapsed
days from first to last treatment fraction.
Follow-up
Patients were followed with physical examination and
MRI imaging at 3 to 6 month intervals per routine insti-
tutional practice. Local tumor recurrence was defined as
progression of the treated tumor based on official radio-
logical review of follow-up imaging and included in-
creased tumor size, enhancement, mass effect, and/or
vasogenic edema. Radiation necrosis was defined based
on official radiological review of follow-up imaging and
in many cases included MR perfusion scan. In all cases a
single radiation oncologist also reviewed follow up im-
aging. All cases involving a question of tumor recur-
rences versus radionecrosis were routinely discussed at
our interdisciplinary neurological tumor conference. If a
neuroradiologist was unable to differentiate recurrence
from radionecrosis using an MRI alone, an MR perfu-
sion scan was obtained. If MR perfusion was also
equivocal, then MRI spectroscopy was subsequently ob-
tained. Radiation necrosis was confirmed pathologically
in those cases requiring surgical intervention. Toxicities
were scored according to the National Cancer Institute
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Common Terminology Criteria for Adverse Events,
Version 3.0 (National Institutes of Health, 2006).
Statistical analysis
Statistical analysis was performed with the MedCalc
Statistical Software version 13.0 (MedCalc Software;
Ostend, Belgium; 2014). The follow-up duration was de-
fined as the time from the date of treatment completion
to the last date of follow-up or the date of death. Com-
parison of dosimetric parameters between patients who
did and did not develop radionecrosis was performed
using the Students t-Test (one-tailed equal variance distri-
bution). Actuarial local control and overall survival were
calculated using the Kaplan-Meier method.
Results
Patient characteristics
Twenty patients with a median age of 65.5 years (37 to
94 years) were treated from April 2010 to August 2014.
The majority was male (60 %) and the primary histology
treated was adenocarcinoma (90 %). The remainder of
histologic variants included one squamous and one ade-
nosquamous subtype. Pretreatment median ECOG per-
formance status and RPA prognostic class were 1 and 2,
respectively. Distribution of tumor location was as follows:
7 parietal, 6 frontal, 2 occipital, 2 cerebellar, 1 brainstem, 1
basal ganglia, and 1 temporal. Forty-five percent of
patients were treated with chemotherapy prior to SRS
treatment. Four of the 18 patients (22 %) diagnosed with
adenocarcinoma were found to be EGFR mutation car-
riers, and 3 of these patients were treated with prior erloti-
nib. Specific patient characteristics are shown in Table 1.
Treatment characteristics
Patients were treated using the CyberKnife® SRS system
to a median dose of 35 Gy (30 to 40 Gy) all in 5 frac-
tions. Treatment plans were composed of hundreds of
pencil beams delivered using a single 10 to 35 mm diam-
eter collimator. Median treatment length from start to
completion of SRS was 7 days (5 to 16 days). Of note, one
patient was hospitalized with pneumonia during their
course of fractionated treatment causing a treatment delay
of 11 days. Mean tumor volume (GTV) treated was
7.55 cc (0.35 to 42.63 cc) and median tumor volume
treated was 5.56 cc. Treatment was delivered to a median
prescription isodose line of 83 % (75 to 90 %) with median
GTV target coverage of 99.88 % (97.15 to 100 %) and aver-
age conformality index of 1.63. Specific treatment charac-
teristics are shown in Table 2.
Outcomes
At a median follow-up of 11.3 months local tumor control
was observed in 18 of 20 brain metastases (90 %). Mean
time to local intracranial progression was 5.59 months.
Both local failures were observed in patients receiving a
total dose of 30 Gy. Median pre-treatment dexamethasone
dose was 10 mg/day and median post-treatment nadir
dose was 0 mg/day. Distant intracranial failure was ob-
served in 8 of 20 patients (40 %) and any intracranial pro-
gression was observed in 10 of 20 patients (50 %). Salvage
intracranial therapy was required in 45 % of patients.
Salvage therapy was performed with SRS in 4 cases,
WBRT in 3 cases, and surgery in 2 cases. Specific clinical
outcome data is shown in Table 3.
Radiation necrosis was observed in 4 of 20 patients
(20 %), two of which were treated to a total dose of
40 Gy and the remainder to 35 Gy. Radionecrosis was
radiologically confirmed with MRI and MR perfusion
scans in all four cases with MRI spectroscopy also ob-
tained for verification in one case. Two radiation
Table 1 Patient characteristics
Characteristic No. of patients (%)
Age
< 60 5 (25)
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necrosis events eventually required surgical intervention
(grade 4), one required steroid treatment (grade 2), and
one was asymptomatic and diagnosed radiographically
(grade 1). Mean and median time to a radiation necrosis
event was 10.9 and 11.0 months, respectively. Anatom-
ical location was not consistent in those cases leading to
radionecrosis with primary tumors being localized to a
different region in each case (parietal, cerebellar, frontal,
and occipital). Of the patients who subsequently devel-
oped radionecrosis, 2 were treated with prior chemo-
therapy and none were EGFR mutation carriers. GTV
size did not appear to be significantly associated with
radionecrosis (p = 0.44). However, maximum dose was a
statistically significant predictor (p = 0.042) of subse-
quent radionecrosis. Specific radiation necrosis details
are shown in Table 4.
Kaplan-Meier 1-year and 2-year local control was both
90 % (Fig. 1). Kaplan-Meier 1-year, 2-year, and median
survival were calculated to be 45 %, 20 %, and 13.2 months,
respectively (Fig. 2). Ten percent of patients died of intra-
cranial progression one of which was local and the other
distant. Extracranial metastatic progression was the cause
of death for 45 % of patients.
Discussion
NSCLC continues to be the most common cause of can-
cer mortality in the United States. The majority of patients
with NSCLC are diagnosed with metastatic disease at
presentation, thus the appropriate management of those
with a finite number of brain metastases is crucial. Pa-
tients with single brain metastases have been traditionally
managed with a combination of surgery, WBRT, and/or
SRS. Single fraction SRS is the most commonly utilized
and prospectively validated SRS approach [5]. However,
high-risk NSCLC brain metastases, those of large size or
localized within an eloquent cortex, have limited the util-
ity of this established single-fraction SRS technique [6, 7,
11]. Modern evidence suggests widening the therapeutic
window with fractionated SRS may be a suitable alterna-
tive in order to provide high dose conformal radiotherapy
while exploiting the radiobiological properties of normal
tissues [12, 13].
Established single-dose SRS has been compared to frac-
tionated SRS in the definitive treatment of brain metasta-
ses in several retrospective studies. Kim et al. reported an
analysis of patients treated with single-dose SRS (median
dose of 20 Gy) and fractionated SRS (median dose of
36 Gy in 6 fractions) [8]. With a median follow-up of
7 months, 1-year local progression-free survival was not
significantly different between the two groups (p = 0.31).
This was particularly impressive given the lesions treated
with fractionated therapy were larger (median PTV 5.00
vs. 2.21 mL) and/or in more adverse locations. Import-
antly, treatment toxicity was significantly higher in the
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single-dose SRS group versus the fractionated SRS group
(17 % vs. 5 %, p = 0.05). A single institution retrospective
comparison of single fraction (median dose of 16 Gy) vs.
multi-fraction (25 to 30 Gy in 5 fractions) SRS for large
brain metastases (≥8 ml) was also been reported by
Seymour et al. who again showed comparable local con-
trol between the two treatment techniques [12]. These
series and others in the literature support the notion that
hypofractionated SRS can achieve similar local control
and potentially lower neurotoxicity to that seen with
single-fraction SRS [14].
An analogous study published by Ogura et al. exam-
ined their series of 39 consecutively treated patients with
high-risk metastatic brain lesions [13]. In this series,
“high-risk” was similarly defined as lesions localized
within an eloquent cortex, large tumors > 1.5 cm, and/or
those patients with a prior history of WBRT. Linac-based
SRS was used to treat the GTV with a 1 mm margin to a
total dose of 35 Gy in five fractions prescribed to the iso-
center. With a median follow up of 10.81 months the
6- and 12-month local control rates were found to be
92.1 % and 86.7 %, respectively. Of note, the median tumor
volume treated by Ogura et al. was much smaller (3.67 cc
vs. 5.58 cc) in comparison to our study and despite this
smaller tumor volume our 1-year local control was slightly
higher (90 %). This could in part be explained by the
differences observed when prescribing to isocenter where
one expects peripheral tumor dose to be colder relative to
a plan prescribing to a specific GTV-encompassing iso-
dose line as was done in the present study.
Management of even larger brain lesions with more
moderate hypofractionation has been reported in the
literature. Jiang published a series of 40 patients with
brain lesions > 3 cm (median GTV volume of 17.48 cc)
treated to a median dose of 40 Gy in 10 fractions [15].
Additionally, over half of these patients received an SRS
boost 1–3 months after the first course of radiation to a
median dose of 20 Gy in 4 fractions. This unique treat-
ment approach allowed for dose escalation with an SRS
boost to a smaller treatment volume several months
following initial treatment course after many tumors have
regressed in size. An excellent local control of 94.2 % was
observed with one death from severe radionecrosis at
1-year, which translated into a median survival time of
14 months. Moderate hypofractionation of 40 Gy in 10
fractions for large brain metastases (>15 cc) has also been
supported over shorter course treatments by Fahrig et al.
and elsewhere in the literature [16, 17].
Table 4 Radiation necrosis details
Age Sex Location Histology GTV (cm3) Total dose (Gy) Max dose (Gy) Prior chemo. Symptoms Treatment
65 M Parietal Adeno. 0.62 40 53.3 Yes None None
66 M Cerebellar Adeno. 13.5 40 43.2 None LLE ataxia Steroids
58 M Frontal Adeno. 10.5 35 41.2 Yes AMS Surgery
65 F Occipital Adeno. 8.51 35 41.2 None Visual Surgery
Fig. 1 Kaplan-Meier local control from time of completion of hypofractionated radiotherapy treatment
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One of the primary goals of fractionated SRS is reduc-
tion of late toxicity and in particular radiation necrosis.
Estimates of radiation necrosis in the literature place the
incidence between 5 and 10 % with an increased inci-
dence observed in larger tumors treated with single-
fraction SRS [3, 18, 19]. Nevertheless, diagnosis of radi-
ation necrosis is fraught with difficulty in distinguishing
it from true local recurrence. The relatively high rate of
radiation necrosis observed in the present study (20 %)
was largely driven by the high SRS doses (40 Gy) used in
half of the observed cases. In our small sample, tumor
size and location did not seem to correlate with subse-
quent progression of radionecrosis. However, as one
would expect given two necrosis events occurred after a
total dose of 40 Gy, maximum dose was significantly as-
sociated with radiation necrosis. Ogura et al. analogously
reported observing their only radiation necrosis event
following administration of 40 Gy though this patient
also previously received WBRT. Minniti et al. reported a
9 % 1-year risk of radionecrosis causing severe neuro-
logical complications with the most significant predictor
of risk a V21 > 20.9 cc [3]. A correlation between exten-
sive radiation necrosis and V14 ≥ 7.0 cc in 5-fraction
SRS has also been reported by Inoue et al. with no re-
ported radionecrosis in those treated with a V14 < 7 cc
[20]. Although additional prospective studies exploring
dose fractionation in high-risk lesions will be critical,
this limited data seems to suggest an upper limit to
be wary of in both previously radiated and unirradi-
ated patients.
As data continues to accumulate supporting the effi-
cacy and safety of hypofractionated SRS, the ideal dose
and fractionation schedule continues to be unknown.
There may, however, be a radiobiological minimum to
achieve suitable local control. Wiggenraad et al. reported
that BED12 of at least 40 Gy is required to produce ac-
ceptable local control (≥70 %) of brain metastases based
on a systemic literature review of SRS dose and local
control probability [18]. This corresponded to a single-,
two-, and three-fraction dose of 20 Gy, 11.6 Gy, and
8.5 Gy. Using an α/β value of 12 Gy for brain metastases
the recommended schedule utilized in our study of
35 Gy in five fractions yields an approximate BED of
55.42 Gy and as reported yielded a local control well
over 70 %. In our homogenous population of patients all
with NSCLC brain metastases a high α/β value of 12 Gy
is by all accounts a reasonable estimate. However, the
variability in radiosensitivity among metastases of differ-
ent histologies with distinct α/β values will likely require
distinct BED minimums for fractionated SRS therapy.
Our study reports the efficacy of a 5-fraction SRS
treatment regimen for single high-risk brain metastases
diagnosed in patients with metastatic NSCLC. Following
definitive radiation treatment virtually all patients in this
study were weaned from their initial pre-treatment dose
of corticosteroids. As described, the total dose ranged
from 30 to 40 Gy all delivered in 5 fractions. Both local
failures occurred at the lower total dose level of 30 Gy.
One of these lesions was a particularly aggressive pontine
lesion, which caused prominent neurological symptoms
prior to treatment and progressed shortly thereafter. Of
the reported radiation necrosis events half occurred at
the higher 40 Gy total dose level. As such, based on this
small cohort of patients it appears a total dose of 35 Gy in
Fig. 2 Kaplan-Meier overall survival from time of completion of hypofractionated radiotherapy treatment
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5-fractions is the optimal schedule to achieve durable local
control while simultaneously minimizing normal toxicity
in these high-risk cases.
Limitations of the present study include the small
patient population and its retrospective analysis. An
ongoing prospective trial conducted by Minniti et al.
aims to determine whether 27 Gy in 3 fractions or
the 35 Gy in 5 fractions, proposed by this study, is most
efficacious [3]. Other future research should continue to
address the optimal fractionation schedule for high-risk
brain metastases.
Conclusion
Five-fraction SRS to a total dose of 35 Gy appears to be
a safe and effective management strategy for single high-
risk inoperable NSCLC brain metastases. Based on this
preliminary data, five-fraction SRS to a total dose of
40 Gy appears to result in an excess risk of radionecrosis
in patients with these high risk lesions. Additional re-
search will be required to confirm our preliminary
encouraging findings and to establish the optimal dose
and fractionation schedule for the treatment of high-risk
brain metastases.
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